New Zealand markets open in 8 hours 19 minutes

BIIB Jan 2023 170.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
As of 02:14PM EST. Market open.
Full screen
Previous close0.2000
Open0.1000
Bid0.0000
Ask0.0000
Strike170.00
Expiry date2023-01-20
Day's range0.1000 - 0.2000
Contract rangeN/A
Volume2
Open interest3.93k
  • GlobeNewswire

    European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

    SOD1-ALS is a rare, genetic form of ALS,1 comprising approximately 2% of people with ALS2If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-AL

  • Motley Fool

    Can These 2 Stocks Crush the Market Again in 2023?

    The list includes Regeneron Pharmaceuticals (NASDAQ: REGN) and Biogen (NASDAQ: BIIB). Regeneron was having an unimpressive year on the stock market until its shares soared by double-digit percentages in one day in September. As is often the case with biotechs, Regeneron owes this move to positive clinical developments.

  • Motley Fool

    Is Biogen Stock a Buy Now?

    Thanks to well-received clinical trial data for its investigational Alzheimer's therapy, lecanemab, shares of Biogen (NASDAQ: BIIB) are up by more than 51% in the past three months -- and the company hasn't even made a single dollar from the positive findings yet. Including lecanemab, Biogen has a dozen programs in late-stage clinical trials, all but four of which are being developed for indications in neurology. Its areas of focus within neurology are Alzheimer's disease and Parkinson's disease, though it also has a trio of programs for multiple sclerosis (MS) in development.